The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
Open accessAbstract
Background and purpose: Inhibition of cholesteryl ester transfer protein (CETP) with torcetrapib in humans increases plasma high density lipoprotein (HDL) cholesterol levels but is associated with increased blood pressure. In a phase 3 clinical study, evaluating the effects of torcetrapib in atherosclerosis, there was an excess of deaths and adverse cardiovascular events in patients taking torcetrapib. The studies reported herein sought to evaluate off‐target effects of torcetrapib. Experimental approach: Cardiovascular effects of the CETP inhibitors torcetrapib and anacetrapib were evaluated in animal models. Key results: Torcetrapib evoked an acute increase in blood pressure in all species evaluated whereas no increase was observed with anacetrapib. The pressor effect of torcetrapib was not diminished in the presence of adrenoceptor, angiotensin II or endothelin receptor antagonists. Torcetrapib did not have a contractile effect on vascular smooth muscle suggesting its effects in vivo are via the release of a secondary mediator. Treatment with torcetrapib was associated with an increase in plasma levels of aldosterone and corticosterone and, in vitro , was shown to release aldosterone from adrenocortical cells. Increased adrenal steroid levels were not observed with anacetrapib. Inhibition of adrenal steroid synthesis did not inhibit the pressor response to torcetrapib whereas adrenalectomy prevented the ability of torcetrapib to increase blood pressure in rats. Conclusions and implications: Torcetrapib evoked an acute increase in blood pressure and an acute increase in plasma adrenal steroids. The acute pressor response to torcetrapib was not mediated by adrenal steroids but was dependent on intact adrenal glands. British Journal of Pharmacology (2008) 154 , 1465–1473; doi: fn2 ; published online 9 June 2008
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162 · cited 1×
“This strategy is predicated on the strong epidemiologic data that document an inverse correlation between HDL levels and coronary heart disease (Gordon et al., 1989; Assmann and Schulte, 1992).”
BackgroundEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
PITT, B., ZANNAD, F., REMME, W. J., CODY, R., CASTAIGNE, A., PEREZ, A., PALENSKY, J., & WITTES, J. (2000) · Survey of Anesthesiology · doi:10.1097/00132586-200006000-00059 · Cited by 2,927
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Current Perspectives on Statins
Maron, D. J., Fazio, S., & Linton, M. F. (2000) · Circulation · doi:10.1161/01.cir.101.2.207 · Cited by 1,213
Regulation of the acute production of steroids in steroidogenic cells
STOCCO, D. M., & CLARK, B. J. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-3-221 · Cited by 1,057
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Assmann, G., & Schulte, H. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)90550-i · Cited by 872
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Regulation of the acute production of steroids in steroidogenic cells
Stocco, D. M. (1996) · Endocrine Reviews · doi:10.1210/er.17.3.221 · Cited by 626
Serum Aldosterone and the Incidence of Hypertension in Nonhypertensive Persons
Vasan, R. S., Evans, J. C., Larson, M. G., Wilson, P. W. F., Meigs, J. B., Rifai, N., Benjamin, E. J., & Levy, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033263 · Cited by 571
A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits
Okamoto, H., Yonemori, F., Wakitani, K., Minowa, T., Maeda, K., & Shinkai, H. (2000) · Nature · doi:10.1038/35018119 · Cited by 531
de Grooth, G. J., Kuivenhoven, J. A., Stalenhoef, A. F. H., de Graaf, J., Zwinderman, A. H., Posma, J. L., van Tol, A., & Kastelein, J. J. P. (2002) · Circulation · doi:10.1161/01.cir.0000015857.31889.7b · Cited by 456
Clark, R. W., Sutfin, T. A., Ruggeri, R. B., Willauer, A. T., Sugarman, E. D., Magnus-Aryitey, G., Cosgrove, P. G., Sand, T. M., Wester, R. T., Williams, J. A., et al. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000118278.21719.17 · Cited by 371
The new biology of aldosterone
Connell, J. M. C., & Davies, E. (2005) · Journal of Endocrinology · doi:10.1677/joe.1.06017 · Cited by 356
Effects of Aldosterone on the Vasculature
Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000201443.63240.a7 · Cited by 303
The Pathophysiology of Aldosterone in the Cardiovascular System
ROCHA, R., & FUNDER, J. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04415.x · Cited by 261
The role of corticosteroids in the regulation of vascular tone
Ullian, M. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(98)00230-2 · Cited by 260
Sugano, M., Makino, N., Sawada, S., Otsuka, S., Watanabe, M., Okamoto, H., Kamada, M., & Mizushima, A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.9.5033 · Cited by 241
McKenney, J. M., Davidson, M. H., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.066 · Cited by 144
Keidar, S., Hayek, T., Kaplan, M., Pavlotzky, E., Hamoud, S., Coleman, R., & Aviram, M. (2003) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-200306000-00019 · Cited by 130
Davidson, M. H., McKenney, J. M., Shear, C. L., & Revkin, J. H. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.06.067 · Cited by 129
Fredlund, P., Saltman, S., & Catt, K. J. (1975) · Endocrinology · doi:10.1210/endo-97-6-1577 · Cited by 104
Eveland, S. S., Milot, D. P., Guo, Q., Chen, Y., Hyland, S. A., Peterson, L. B., Jezequel, S., O’Donnell, G. T., Zuck, P. D., Ferrer, M., et al. (2007) · Analytical Biochemistry · doi:10.1016/j.ab.2007.06.003 · Cited by 24
Self-citation
Cited by
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Effects of anacetrapib in patients with atherosclerotic vascular disease
The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047
Safety of anacetrapib in patients with or at high risk for coronary heart disease
Cannon, C. P., Shah, S., Dansky, H. M., Davidson, M., Brinton, E. A., Gotto, A. M., Stepanavage, M., Liu, S. X., Gibbons, P., Ashraf, T. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1009744 · Cited by 749
Lüscher, T. F., Landmesser, U., von Eckardstein, A., & Fogelman, A. M. (2014) · Circulation Research · doi:10.1161/circresaha.114.300935 · Cited by 291
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Metadata
- Authors
- Forrest, M. J., Bloomfield, D., Briscoe, R. J., Brown, P. N., Cumiskey, A., Ehrhart, J., Hershey, J. C., Keller, W. J., Ma, X., McPherson, H. E., Messina, E., Peterson, L. B., Sharif‐Rodriguez, W., Siegl, P. K. S., Sinclair, P. J., Sparrow, C. P., Stevenson, A. S., Sun, S., Tsai, C., Vargas, H., Walker, M., West, S. H., White, V, & Woltmann, R. F.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2008-08
- Volume
- 154
- Issue
- 7
- Pages
- 1465-1473
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2063992255
- Cited by
- 292
- References
- 32
- FWCI
- 28.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.